Mesuximide
Appearance
(Redirected from Celontin)
![]() | |
Clinical data | |
---|---|
Trade names | Celontin |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682028 |
Routes of administration | By mouth (capsules) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic (demethylation and glucuronidation) |
Metabolites | N-desmethylmethosuximide |
Elimination half-life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.934 |
Chemical and physical data | |
Formula | C12H13NO2 |
Molar mass | 203.241 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
![]() ![]() |
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
Medical use
[edit]is indicated for the control of absence seizures that are refractory to other drugs.[2]
References
[edit]- ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
- ^ a b Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
- ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.